composite biomarkers predictive of palbociclib endocrine treatment benefit in early breast cancer
Published 1 year ago • 113 plays • Length 1:43Download video MP4
Download video MP3
Similar videos
-
1:10
palbociclib, pembrolizumab, and endocrine therapy in hr /her2- breast cancer
-
1:55
predictive biomarkers in breast cancer
-
2:39
the role of biomarkers in guiding treatment for early-stage breast cancer
-
5:00
penelope-b: palbociclib with endocrine therapy in hr , her2-negative breast cancer
-
1:45
identifying novel predictive biomarkers in breast cancer
-
7:26
i-spy 2: immunotherapy biomarkers in early breast cancer
-
0:56
gut microbiome and treatment outcomes in hr /her2- breast cancer
-
0:55
prognostic biomarkers of immunotherapy efficacy in breast cancer
-
6:08
prognostic biomarkers in breast cancer – the latest developments
-
0:35
duration of endocrine therapy in early breast cancer
-
0:44
across-trop2: identifying predictive biomarkers of sg in hr /her2- breast cancer
-
4:02
assessment of short preoperative endocrine therapy in the adapt and adaptcycle trials
-
0:42
what future does ctdna have as a biomarker in breast cancer?
-
6:47
palbociclib: single-agent or in combination for the treatment of breast cancer
-
6:45
innovative biomarker approaches in breast cancer therapy
-
0:43
predicting treatment outcomes in head and neck cancers with biomarkers
-
2:46
ameera-3: amcenestrant does not improve pfs in er /her2- breast cancer
-
1:14
the importance of a biomarker-directed approach in triple-negative breast cancer
-
6:09
ki-67 index after neoadjuvant et as a prognostic biomarker for hr /her2- early breast cancer